Related Experiment Video
Updated: Mar 16, 2026
Implantation of Total Artificial Heart in Congenital Heart Disease
Published on: July 18, 2014
Heart Transplantation-The Pediatric Cardiac Critical Care Perspective
Joseph W Rossano1, Antonio G Cabrera, Robert E Shaddy
11Department of Pediatrics, Section of Cardiology, The Perelman School of Medicine at the University of Pennsylvania, The Children's Hospital of Philadelphia, Philadelphia, PA. 2Department of Pediatrics, Section of Cardiology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX.
Insights
Pediatric heart transplantation is crucial for end-stage heart disease. Managing allograft dysfunction and understanding immunosuppressive medications are key for improving long-term survival in these complex pediatric ICU patients.
Area of Science:
- Pediatric Cardiology
- Critical Care Medicine
- Transplantation Immunology
Background:
- Heart transplantation is the standard therapy for pediatric end-stage heart disease.
- Pediatric heart transplant recipients are a complex patient group often requiring intensive care.
- Allograft dysfunction is a significant limitation to long-term survival post-transplant.
Purpose of the Study:
- To review the causes of allograft dysfunction in pediatric heart transplant recipients.
- To discuss the management strategies for allograft dysfunction.
- To outline the medications used in the pediatric transplant population.
Main Methods:
- Literature review of MEDLINE, PubMed, and Cochrane Database of systemic reviews.
- Synthesis of current knowledge on pediatric heart transplant complications.
- Analysis of immunosuppressive medication effects and side effects.
Main Results:
- Allograft dysfunction can arise from various etiologies at different time points post-transplantation.
- Immunosuppressive medications are vital but associated with significant short- and long-term complications.
- Effective management of allograft dysfunction is critical for improving patient outcomes.
Conclusions:
- Pediatric heart transplant recipients present unique challenges in the ICU setting.
- Understanding and managing allograft dysfunction is paramount for enhancing long-term survival.
- Careful consideration of immunosuppressive regimens is essential to mitigate complications.
Objectives:
Although there have been tremendous advancements in the care of severe pediatric cardiovascular disease, heart transplantation remains the standard therapy for end-stage heart disease in children. As such, these patients comprise an important and often complex subset of patients in the ICU. The purpose of this article is to review the causes and management of allograft dysfunction and the medications used in the transplant population.
Data Sources:
MEDLINE, PubMed, and Cochrane Database of systemic reviews.
Conclusions:
Pediatric heart transplant recipients represent a complex group of patients that frequently require critical care. Their immunosuppressive medications, while being vital to maintenance of allograft function, are associated with significant short- and long-term complications. Graft dysfunction can occur from a variety of etiologies at different times following transplantation and remains a major limitation to long-term posttransplant survival.
Related Concept Videos
01:29Cardiomyopathy V: Interprofessional Care
01:28Kidney Transplant I: Introduction